Accordingly, the NHBPEP (National High Blood Pressure Education Program) and ACOG (American College of Obstetricians and Gynecologists) offer recommendations (methyldopa, nifedipine, hydralazine and labetalol as first-line agents), while angiotensin-converting-enzyme (ACE) inhibitors are not recommended during pregnancy [36,37,38]. This evidence concerns the gene ACE and blood pressure trait.